피부 대체재 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 용도별, 최종 용도별, 지역별 및 부문별 예측(2026-2033년)

Skin Substitutes Market Summary

The global skin substitutes market size was valued at USD 1.9 billion in 2025 and is projected to grow from USD 2.3 billion in 2026 to USD 4.9 billion by 2033, at a CAGR of 11.7% from 2026 to 2033. North America dominated the skin substitutes market with the largest revenue share of 41.3% in 2025. The growth of the global skin substitutes market is driven by the rising prevalence of chronic wounds, diabetic foot ulcers, burns, and pressure ulcers worldwide.

Increasing adoption of advanced wound care solutions, growing geriatric populations, and rising healthcare expenditure are driving demand for regenerative therapies.

The rising prevalence of diabetes and its associated complications, particularly diabetic foot ulcers (DFUs), is a major driver for the growth of the skin substitutes market. Diabetes impairs wound healing due to reduced blood circulation, neuropathy, and increased risk of infections, leading to a higher demand for advanced wound care solutions. The increasing number of diabetic patients across U.S. states and globally is expanding the patient pool requiring regenerative therapies, including biological and synthetic skin substitutes, to accelerate tissue repair and reduce amputation risks.

Global Skin Substitutes Market Report Segmentation

This report forecasts revenue growth at global, regional & country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global skin substitutes market report based on product, application, end use, and region:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Biological Skin Substitute
  • Human Donor Tissue-derived Products
  • Acellular Animal-derived Products
• Synthetic Skin Substitute
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Acute Wounds
• Chronic Wounds
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals
• Outpatient Facilities
• Research and Manufacturing
• Regional Outlook (Revenue, USD Million, 2021-2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Thailand
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Product
  • 1.1.2. Application
  • 1.1.3. End Use
  • 1.1.4. Regional scope
  • 1.1.5. Estimates and forecast timeline
• 1.2. Market Definitions
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
• 1.5. Details of primary research
  • 1.5.1. Data for primary interviews in North America
  • 1.5.2. Data for primary interviews in Europe
  • 1.5.3. Data for primary interviews in Asia Pacific
  • 1.5.4. Data for primary interviews in Latin America
  • 1.5.5. Data for Primary interviews in MEA
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.1.1. Approach 1: Commodity flow approach
  • 1.7.2. Volume price analysis (Model 2)
    • 1.7.2.1. Approach 2: Volume price analysis
• 1.8. Research Scope and Assumptions
  • 1.8.1. List of Secondary Sources
  • 1.8.2. List of Primary Sources
  • 1.8.3. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Skin Substitutes Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Drivers Analysis
    • 3.2.1.1. Increasing prevalence of chronic wounds
    • 3.2.1.2. Technological advancements in skin substitutes
    • 3.2.1.3. Rising geriatric population across the globe
    • 3.2.1.4. Increasing surgical procedures
    • 3.2.1.5. Growing burn and trauma cases
  • 3.2.2. Market Restraints Analysis
    • 3.2.2.1. High cost of skin substitute products
  • 3.2.3. Market Opportunity Analysis
    • 3.2.3.1. Rising distribution agreement for skin substitutes
    • 3.2.3.2. Expansion of manufacturing and distribution facilities
    • 3.2.3.3. Growing demand for aesthetic procedures
    • 3.2.3.4. Expansion in emerging markets
  • 3.2.4. Market Challenge Analysis
    • 3.2.4.1. Intense competition
• 3.3. Skin Substitutes Market Analysis Tools
  • 3.3.1. Porter's Analysis
    • 3.3.1.1. Bargaining power of the suppliers
    • 3.3.1.2. Bargaining power of the buyers
    • 3.3.1.3. Threats of substitution
    • 3.3.1.4. Threats from new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic and Social landscape
    • 3.3.2.3. Technological landscape
    • 3.3.2.4. Environmental landscape
    • 3.3.2.5. Legal landscape

Chapter 4. Skin Substitutes Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Skin Substitutes Market: Product Movement Analysis, 2025 & 2033 (USD Million)
• 4.3. Global Skin Substitutes Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
• 4.4. Biological Skin Substitute
  • 4.4.1. Biological skin substitute market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.4.2. Human Donor Tissue-derived Products
    • 4.4.2.1. Human donor tissue-derived products market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.4.3. Acellular Animal-derived Products
    • 4.4.3.1. Acellular animal-derived products market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 4.5. Synthetic Skin Substitute
  • 4.5.1. Synthetic skin substitute market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 5. Skin Substitutes Market: Application Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Skin Substitutes Market: Application Movement Analysis, 2025 & 2033 (USD Million)
• 5.3. Global Skin Substitutes Market Size & Trend Analysis, by Application 2021 to 2033 (USD Million)
• 5.4. Acute Wounds
  • 5.4.1. Acute wounds market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 5.5. Chronic Wounds
  • 5.5.1. Chronic wounds market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 6. Skin Substitutes Market: End Use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Skin Substitutes Market: End Use Movement Analysis, 2025 & 2033 (USD Million)
• 6.3. Global Skin Substitutes Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
• 6.4. Hospitals
  • 6.4.1. Hospitals market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 6.5. Outpatient facilities
  • 6.5.1. Outpatient facilities market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 6.6. Research and manufacturing
  • 6.6.1. Research and manufacturing market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 7. Skin Substitutes Market: Regional Estimates & Trend Analysis by Product, Application, and End Use

• 7.1. Regional Dashboard
• 7.2. Market Size and Trend Analysis, 2021 to 2033
• 7.3. North America
  • 7.3.1. North America skin substitutes market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.3.2. U.S.
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Competitive scenario
    • 7.3.2.3. Regulatory framework
    • 7.3.2.4. Reimbursement scenario
    • 7.3.2.5. U.S. skin substitutes market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.3.3. Canada
    • 7.3.3.1. Key country dynamics
    • 7.3.3.2. Competitive scenario
    • 7.3.3.3. Regulatory framework
    • 7.3.3.4. Reimbursement scenario
    • 7.3.3.5. Canada skin substitutes market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.3.4. Mexico
    • 7.3.4.1. Key country dynamics
    • 7.3.4.2. Competitive scenario
    • 7.3.4.3. Regulatory framework
    • 7.3.4.4. Reimbursement scenario
    • 7.3.4.5. Mexico skin substitutes market estimates and forecasts, 2021 - 2033 (USD Million)
• 7.4. Europe
  • 7.4.1. Europe skin substitutes market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.2. UK
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Competitive scenario
    • 7.4.2.3. Regulatory framework
    • 7.4.2.4. Reimbursement scenario
    • 7.4.2.5. UK skin substitutes market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.3. Germany
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Competitive scenario
    • 7.4.3.3. Regulatory framework
    • 7.4.3.4. Reimbursement scenario
    • 7.4.3.5. Germany skin substitutes market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.4. France
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Competitive scenario
    • 7.4.4.3. Regulatory framework
    • 7.4.4.4. Reimbursement scenario
    • 7.4.4.5. France skin substitutes market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.5. Italy
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Competitive scenario
    • 7.4.5.3. Regulatory framework
    • 7.4.5.4. Reimbursement scenario
    • 7.4.5.5. Italy skin substitutes market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.6. Spain
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Competitive scenario
    • 7.4.6.3. Regulatory framework
    • 7.4.6.4. Reimbursement scenario
    • 7.4.6.5. Spain skin substitutes market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.7. Sweden
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Competitive scenario
    • 7.4.7.3. Regulatory framework
    • 7.4.7.4. Reimbursement scenario
    • 7.4.7.5. Sweden skin substitutes market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.8. Denmark
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Competitive scenario
    • 7.4.8.3. Regulatory framework
    • 7.4.8.4. Reimbursement scenario
    • 7.4.8.5. Denmark skin substitutes market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.9. Norway
    • 7.4.9.1. Key country dynamics
    • 7.4.9.2. Competitive scenario
    • 7.4.9.3. Regulatory framework
    • 7.4.9.4. Reimbursement scenario
    • 7.4.9.5. Norway skin substitutes market estimates and forecasts, 2021 - 2033 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Asia Pacific skin substitutes market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5.2. China
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Competitive scenario
    • 7.5.2.3. Regulatory framework
    • 7.5.2.4. Reimbursement scenario
    • 7.5.2.5. China skin substitutes market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5.3. Japan
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Competitive scenario
    • 7.5.3.3. Regulatory framework
    • 7.5.3.4. Reimbursement scenario
    • 7.5.3.5. Japan skin substitutes market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5.4. India
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Competitive scenario
    • 7.5.4.3. Regulatory framework
    • 7.5.4.4. Reimbursement scenario
    • 7.5.4.5. India skin substitutes market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5.5. South Korea
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Competitive scenario
    • 7.5.5.3. Regulatory framework
    • 7.5.5.4. Reimbursement scenario
    • 7.5.5.5. South Korea skin substitutes market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5.6. Australia
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Competitive scenario
    • 7.5.6.3. Regulatory framework
    • 7.5.6.4. Reimbursement scenario
    • 7.5.6.5. Australia skin substitutes market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5.7. Thailand
    • 7.5.7.1. Key country dynamics
    • 7.5.7.2. Competitive scenario
    • 7.5.7.3. Regulatory framework
    • 7.5.7.4. Reimbursement scenario
    • 7.5.7.5. Thailand skin substitutes market estimates and forecasts, 2021 - 2033 (USD Million)
• 7.6. Latin America
  • 7.6.1. Latin America skin substitutes market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.6.2. Brazil
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Competitive scenario
    • 7.6.2.3. Regulatory framework
    • 7.6.2.4. Reimbursement scenario
    • 7.6.2.5. Brazil skin substitutes market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.6.3. Argentina
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Competitive scenario
    • 7.6.3.3. Regulatory framework
    • 7.6.3.4. Reimbursement scenario
    • 7.6.3.5. Argentina skin substitutes market estimates and forecasts, 2021 - 2033 (USD Million)
• 7.7. Middle East and Africa
  • 7.7.1. Middle East and Africa skin substitutes market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.7.2. South Africa
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Competitive scenario
    • 7.7.2.3. Regulatory framework
    • 7.7.2.4. Reimbursement scenario
    • 7.7.2.5. South Africa skin substitutes market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.7.3. Saudi Arabia
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Competitive scenario
    • 7.7.3.3. Regulatory framework
    • 7.7.3.4. Reimbursement scenario
    • 7.7.3.5. Saudi Arabia skin substitutes market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.7.4. UAE
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Competitive scenario
    • 7.7.4.3. Regulatory framework
    • 7.7.4.4. Reimbursement scenario
    • 7.7.4.5. UAE skin substitutes market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.7.5. Kuwait
    • 7.7.5.1. Key country dynamics
    • 7.7.5.2. Competitive scenario
    • 7.7.5.3. Regulatory framework
    • 7.7.5.4. Reimbursement scenario
    • 7.7.5.5. Kuwait skin substitutes market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis by Key Market Participants
• 8.2. Company Categorization
• 8.3. Company Market Share Analysis, 2025
• 8.4. Company Heat Map Analysis
• 8.5. Strategy Mapping
  • 8.5.1. Expansion
  • 8.5.2. Mergers & Acquisition
  • 8.5.3. Partnerships & Collaborations
  • 8.5.4. New Technology Launches
  • 8.5.5. Research And Development
  • 8.5.6. Company Profiles
  • 8.5.7. Organogenesis, Inc.
    • 8.5.7.1. Company overview
    • 8.5.7.2. Financial performance
    • 8.5.7.3. Product Benchmarking
    • 8.5.7.4. Strategic initiatives
  • 8.5.8. PolyNovo Limited
    • 8.5.8.1. Company overview
    • 8.5.8.2. Financial performance
    • 8.5.8.3. Product Benchmarking
    • 8.5.8.4. Strategic initiatives
  • 8.5.9. Integra LifeSciences Corporation
    • 8.5.9.1. Company overview
    • 8.5.9.2. Financial performance
    • 8.5.9.3. Product Benchmarking
    • 8.5.9.4. Strategic initiatives
  • 8.5.10. Smith+Nephew
    • 8.5.10.1. Company overview
    • 8.5.10.2. Financial performance
    • 8.5.10.3. Product Benchmarking
    • 8.5.10.4. Strategic initiatives
  • 8.5.11. Tissue Regenix
    • 8.5.11.1. Company overview
    • 8.5.11.2. Financial performance
    • 8.5.11.3. Product Benchmarking
    • 8.5.11.4. Strategic initiatives
  • 8.5.12. RenovoDerm (ParaGen Technologies)
    • 8.5.12.1. Company overview
    • 8.5.12.2. Financial performance
    • 8.5.12.3. Product Benchmarking
    • 8.5.12.4. Strategic initiatives
  • 8.5.13. MIMEDX Group, Inc.
    • 8.5.13.1. Company overview
    • 8.5.13.2. Financial performance
    • 8.5.13.3. Product Benchmarking
    • 8.5.13.4. Strategic initiatives
  • 8.5.14. Essity Health & Medical. (Essity Aktiebolag (publ))
    • 8.5.14.1. Company overview
    • 8.5.14.2. Financial performance
    • 8.5.14.3. Product Benchmarking
    • 8.5.14.4. Strategic initiatives
  • 8.5.15. Stryker
    • 8.5.15.1. Company overview
    • 8.5.15.2. Financial performance
    • 8.5.15.3. Product Benchmarking
    • 8.5.15.4. Strategic initiatives
  • 8.5.16. Vericel Corporation
    • 8.5.16.1. Company overview
    • 8.5.16.2. Financial performance
    • 8.5.16.3. Product Benchmarking
    • 8.5.16.4. Strategic initiatives
  • 8.5.17. BioTissue (BioStem Technologies)
    • 8.5.17.1. Company overview
    • 8.5.17.2. Financial performance
    • 8.5.17.3. Product Benchmarking
    • 8.5.17.4. Strategic initiatives
  • 8.5.18. PolyMedics Innovations GmbH
    • 8.5.18.1. Company overview
    • 8.5.18.2. Financial performance
    • 8.5.18.3. Product Benchmarking
    • 8.5.18.4. Strategic initiatives
  • 8.5.19. GUNZE LIMITED
    • 8.5.19.1. Company overview
    • 8.5.19.2. Financial performance
    • 8.5.19.3. Product Benchmarking
    • 8.5.19.4. Strategic initiatives
  • 8.5.20. Zimmer Biomet
    • 8.5.20.1. Company overview
    • 8.5.20.2. Financial performance
    • 8.5.20.3. Product Benchmarking
    • 8.5.20.4. Strategic initiatives